NCT00215956View on ClinicalTrials.gov

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Rectal Neoplasms
Interventions
DRUG

topotecan

Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks

PROCEDURE

radiation

Preoperative radiation

PROCEDURE

surgery

surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER